Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI -3.03%53 EV-to-FCF is 5.71 as of Aug. 04, 2026, which is 12% above its 10-year median of 5.12. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 348 Biotechnology companies, Puma Biotechnology ranks better than 61.78% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Puma Biotechnology's Enterprise Value is $305.8 Mil.
Puma Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $53.6 Mil. Therefore, Puma Biotechnology's EV-to-FCF for today is 5.71.
The historical rank and industry rank for Puma Biotechnology's EV-to-FCF or its related term are showing as below:
PBYI'
s EV-to-FCF Range Over the Past 10 Years
Min: -427.82 Med: 5.12 Max: 668.22
Current: 5.71
During the past 13 years, the highest EV-to-FCF of Puma Biotechnology was 668.22. The lowest was -427.82. And the median was 5.12.
PBYI's EV-to-FCF is ranked better than 61.78% of 348
companies
in the Biotechnology industry
Industry Median: 14.235
vs PBYI: 5.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Puma Biotechnology's PE Ratio (TTM) for today is calculated as:
Puma Biotechnology's share price for today is $7.69.
Puma Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Puma Biotechnology EV-to-FCF Related Terms
Puma Biotechnology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Puma Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's EV-to-FCF falls into.
Puma Biotechnology's current Enterprise Value is $305.8 Mil.
Puma Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology (PBYI) has a EV-to-FCF of 5.71 as of Aug. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Puma Biotechnology and its competitors. This is 12% above median its historical median of 5.12. According to the industry distribution chart, Puma Biotechnology ranks #133 out of 348 companies in the Biotechnology industry, placing it in the top 38.2%.
Is Puma Biotechnology's EV-to-FCF too high?
Puma Biotechnology's current EV-to-FCF of 5.71 is 12% above median its 10-year median of 5.12. The Biotechnology industry median EV-to-FCF is 14.24. Puma Biotechnology's value of 5.71 is 59.9% below this industry median. Based on the distribution chart, Puma Biotechnology ranks #133 out of 348 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's EV-to-FCF compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #133 out of 348 companies for EV-to-FCF. This puts Puma Biotechnology in the upper half of its industry. The industry median EV-to-FCF is 14.24. Puma Biotechnology's value of 5.71 is 59.9% below this benchmark. While the company's 10-year median is 5.12 vs. the industry median of 14.24, Puma Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.24, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current EV-to-FCF of 5.71 is 59.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Puma Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current EV-to-FCF is 5.71, which is 12% above median its own 10-year median of 5.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current EV-to-FCF is 5.71, which is 12% above median its 10-year median of 5.12 and 59.9% below the Biotechnology industry median of 14.24. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current EV-to-FCF is 5.71 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
EV-to-FCF: 5.71 (12% above median its 10-year median of 5.12)
GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
Industry Position: 59.9% below the Biotechnology median (#133 of 348)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
